Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 20,000 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. acquired 20,000 shares of the stock in a transaction dated Friday, January 9th. The shares were purchased at an average cost of $16.55 per share, with a total value of $331,000.00. Following the completion of the purchase, the chief executive officer owned 366,155 shares of the company’s stock, valued at approximately $6,059,865.25. The trade was a 5.78% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zenas BioPharma Stock Performance

ZBIO stock opened at $16.08 on Friday. The stock’s fifty day moving average price is $34.94 and its 200-day moving average price is $24.01. The company has a market cap of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma, Inc. has a 1 year low of $5.83 and a 1 year high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Evercore ISI began coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Finally, Morgan Stanley lowered Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $37.00 to $19.00 in a research note on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zenas BioPharma presently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Key Headlines Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider buying — Leon Moulder Jr. purchased roughly $1.63M of ZBIO stock across Jan. 7–9 (aggregate ≈ 100,000 shares), raising his stake to ~366,155 shares. Large, repeated insider purchases often signal management confidence and can support near‑term buying interest from investors. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
• Positive Sentiment: Brokerage sentiment is constructive — analysts’ consensus rating is “Moderate Buy,” which can attract institutional or retail demand if reiterated publicly. This supports a bullish narrative alongside insider purchases. Zenas BioPharma Given Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: Regulatory transparency — multiple SEC filings disclose the CEO’s trades (dates, quantities, prices), confirming the transactions are official and recently reported; useful for verifying timing and cost basis. SEC filing confirming insider purchases
• Neutral Sentiment: Mixed analyst landscape — several firms maintain buy/outperform ratings while others are cautious and price targets vary widely; this leaves upside expectations dispersed among investors. MarketBeat ZBIO analyst summary
• Negative Sentiment: Pomerantz LLP announced an investor alert investigating Zenas BioPharma, creating potential litigation risk and short‑term volatility — such probes can prompt selling pressure until scope and substance are clarified. Pomerantz investigates Zenas BioPharma

Institutional Trading of Zenas BioPharma

Hedge funds have recently made changes to their positions in the business. Quarry LP lifted its stake in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the last quarter. Two Sigma Investments LP increased its holdings in Zenas BioPharma by 3.9% during the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after acquiring an additional 765 shares in the last quarter. Bank of America Corp DE boosted its position in Zenas BioPharma by 5.8% during the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after acquiring an additional 818 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma during the third quarter worth approximately $30,000. Finally, Rhumbline Advisers increased its stake in Zenas BioPharma by 7.6% during the third quarter. Rhumbline Advisers now owns 21,214 shares of the company’s stock worth $471,000 after acquiring an additional 1,493 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.